Scapa Healthcare has enhanced its manufacturing and research and development capabilities at its Knoxville, TN center of excellence (COE). The facility specializes in the design, engineering, and manufacturing of custom skin-friendly fixation solutions including advanced wound dressings, negative pressure wound therapy drapes, consumer bandages, custom wearable solutions for monitoring, fixation and diagnostic devices, and IV dressings. It also produces topical consumer products including medicated powders and topical OTC drugs.

Multimillion dollar investments in this facility have resulted in four innovation and product development labs to provide a collaborative space for the product development, contract design and manufacturing operations for OTC drugs, and the installation of high-speed automated vision systems that enhance process controls to ensure quality and consistency.

The facility is FDA registered for medical device and OTC drug manufacturing, is ISO 9001 and ISO 13485 certified, and has ANVISA GMP clearance. With 152,000 sq ft of manufacturing space and Class 8 cleanroom environments, it utilizes advanced high-precision converting machines and high-speed automated packaging equipment and performs medical device kit assembly. 

“Scapa Healthcare has made significant investments in the Knoxville center of excellence to leverage the power of collaboration between our employees and customers to rapidly bring innovative new products to market,” said John Petreanu, president of Scapa Healthcare, in a news release. “Our customers require not only a dependable partner that provides high-quality products but also a partner that supports their innovation efforts. Our goal is to continue to play an active role as a trusted strategic partner across all our key markets segments, successfully serving our customers to help them meet increasing market demands.”